Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial

Abstract Background Classical Hodgkin lymphoma (cHL) is a highly curable disease, while novel therapy is needed for refractory or relapsed (R/R) patients. This phase II trial aimed to evaluate the role of camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in R/R cHL patients. Methods Transplant-e...

Full description

Bibliographic Details
Main Authors: Yanfei Liu, Lingyan Ping, Yuqin Song, Yongjing Tang, Wen Zheng, Weiping Liu, Zhitao Ying, Chen Zhang, Meng Wu, Feier Feng, Ningjing Lin, Meifeng Tu, Jun Zhu, Yan Xie
Format: Article
Language:English
Published: BMC 2024-03-01
Series:BMC Medicine
Subjects:
Hodgkin disease
Camrelizumab
Gemcitabine
Oxaliplatin
Online Access:https://doi.org/10.1186/s12916-024-03329-8

Internet

https://doi.org/10.1186/s12916-024-03329-8

Similar Items